Literature DB >> 27704540

Antenatal pertussis vaccination: Are we implementing best evidence into practice?

Sushena Krishnaswamy1,2, Euan Wallace1,3,4, Jim Buttery3,5,6,7,8, Michelle Giles1,2,4,6.   

Abstract

Maternal immunisation is the most effective strategy to reduce infant morbidity and mortality from pertussis infection, and is now standard of care in many countries, including Australia. However, uptake cannot be guaranteed unless the barriers to implementing programs locally are understood. Education and resources for antenatal care providers, embedding vaccination within antenatal care, and provision of culturally appropriate information for pregnant women are integral to a successful antenatal vaccination program.
© 2016 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.

Entities:  

Keywords:  maternal immunisation; pertussis; vaccine acceptance; vaccine attitudes; vaccines in pregnancy

Mesh:

Substances:

Year:  2016        PMID: 27704540     DOI: 10.1111/ajo.12554

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  3 in total

1.  Expected challenges of implementing universal pertussis vaccination during pregnancy in Quebec: a cross-sectional survey.

Authors:  Nicholas Brousseau; Dominique Gagnon; Maryline Vivion; Vanessa Poliquin; Isabelle Boucoiran; Bruce Tapiéro; Eve Dubé
Journal:  CMAJ Open       Date:  2018-09-20

2.  Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine.

Authors:  Julianne Bayliss; Michael Nissen; Damita Prakash; Peter Richmond; Kyu-Bin Oh; Terry Nolan
Journal:  Hum Vaccin Immunother       Date:  2020-06-23       Impact factor: 3.452

3.  Is adding maternal vaccination to prevent whooping cough cost-effective in Australia?

Authors:  Laure-Anne Van Bellinghen; Alex Dimitroff; Michael Haberl; Xiao Li; Andrew Manton; Karen Moeremans; Nadia Demarteau
Journal:  Hum Vaccin Immunother       Date:  2018-06-22       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.